source
- Analysts focus on RevMed pancreatic cancer launch and Merck data push ahead of Q3 earningsJohnson & Johnson is set to open the third quarter earnings reporting period, with analysts keen to hear about any business development news and launch execution updates. RevMed’s upcoming launch…
- Novartis secures supplemental FDA approval to market repurposed antibiotic Lamprene in the USNovartis has obtained a supplemental approval from the U.S. Food and Drug Administration for its drug Lamprene, allowing it to be sold as an antibiotic. Lamprene, originally developed decades ago…